MedPage Today (11/7, DePeau-Wilson) reported, “Using long-acting injectable (LAI) antipsychotic therapies rather than oral agents for schizophrenia was tied to demographic and clinical factors, a single-center retrospective cohort study suggested.” Younger age “predicted which patients received LAI antipsychotic treatment,” and “length of first admission also predicted LAI use…said” one researcher. The findings of the 246-patient study were presented at the 2022 Neuroscience Education Institute Congress.
Related Links:
— MedPage Today (requires login and subscription)